The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cabozantinib + nivolumab in adult patients with advanced or metastatic renal cell carcinoma: A retrospective, non-interventional study in a real-world cohort.
 
Thomas Hilser
No Relationships to Disclose
 
Christopher Darr
Travel, Accommodations, Expenses - Janssen
 
Guenter Niegisch
Honoraria - Astellas Pharma; AstraZeneca; Medac; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Merck/Pfizer; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Merck; Roche Pharma AG
 
Marco Julius Schnabel
No Relationships to Disclose
 
Susan Foller
Honoraria - Bristol Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Procept-Biorobotics; Roche Pharma AG
Consulting or Advisory Role - Ipsen; Merck/Pfizer; MSD; Roche
 
Lorine Haeuser
No Relationships to Disclose
 
Stefanie Zschaebitz
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)
Research Funding - Eisai (Inst)
Travel, Accommodations, Expenses - Merck; Pfizer
 
Jonas Lewerich
No Relationships to Disclose
 
Merle Anders-Meyn
No Relationships to Disclose
 
Philipp Ivanyi
Honoraria - AIMM Therapeutics; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD Oncology; Novartis; Roche Pharma AG
Consulting or Advisory Role - Bayer/Vital; Bristol-Myers Squibb; Ipsen; Merck Serono; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen
 
Katrin Schlack
Consulting or Advisory Role - AAA HealthCare; Amgen; Apogepha; Astellas Amgen BioPharama; AstraZeneca; Bayer; BMS GmbH & Co. KG; Eisai; EUSA Pharma; Fosanis; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; AstraZeneca; Bristol-Myers Squibb; ClinSol; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Debiopharm Group; Eisai; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Onkowissen; Pfizer
Research Funding - Amgen (Inst); BMS (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Pfizer